We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Multiplex Assay Detects Six Biothreat Organisms

By LabMedica International staff writers
Posted on 27 Jun 2011
A multiplex biothreat assay kit rapidly detects six organisms, five bacteria and one virus. More...


The product tests for multiple organisms on US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) watch lists with more specificity and at a lower cost than currently available assays

The BioThreat assay kit provides added specificity and selectivity by using a total of 16 genomic and plasmid specific signatures to confirm the presence or absence of an organism. The multicolor combinatorial approach enables the user to screen rapidly a biologic sample for the presence of the five bacteria and one virus in three simultaneous reactions; a traditional singleplex method would require 16 reactions to accomplish the identical task.

The multiplex biothreat assay (MBA) was developed by MicroFluidic Systems (MFSI), a wholly owned subsidiary of PositiveID (Delray Beach, FL, USA). The MBA tests for the following six organisms with 16 organism specific signatures: Bacillus anthracis (Anthrax); Yersinia pestis (Plague); Francisella tularensis (Tularemia); Burkholderia pseudomallei (Melioidosis); Burkholderia mallei (Glanders); and Variola virus major variant (Small Pox).

PositiveID plans initially to target public health and university labs that test for pathogens. Currently available methods require larger amounts of the sample, are generally more costly than MBA, and are not amenable to high-throughput analyses.

Related Links:

US Centers for Disease Control and Prevention
PositiveID




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.